Gregg Stone REFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GREGG STONE, Columbia University, New York New light has been thrown on the u
Gregg StoneREFERENCE: Abstract 2357, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, FloridaGREGG STONE, Columbia University, New YorkNew light has been thrown on the use of thienopyridine therapy after percutaneous intervention using drug-eluting stents.Gregg Stonepresented data from the TAXUS DES trials which looked at patients surviving more than a year after receiving either paclitaxel-eluting or bare metal stents. After his talk at the American Heart Association he discussed his findings with Sarah Maxwell.
Related Episodes
LDL-How Low?
Terje Pedersen Terje Pedersen, Ulleval University, Oslo Eugene Braunwald, Harvard University, Boston Lowering LDL Cholesterol intensively as a means of treating aortic stenosis was found to have no be
Audio Journal of Oncology Volume 16 Number 8
Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna In this edition: Bevacizumab and Survival in Metastatic Breast Cancer Source: N Engl J Med 357:26 George Canellos, Dana-F
Heart Failure Drug Prevents Renal Damage?
Barry Massie Barry Massie, San Francisco VA Medical Center COMMENT: Aaron Kugelmass, Henry Ford Hospital, Detroit The adenosine A1-receptor antagonist rolofylline appears to prevent renal impairment a